Navigation Links
Investigators unveil new drug discovery tool for Alzheimer's disease
Date:4/28/2008

April 28, 2008 -- An article published in the April issue of the Journal of Alzheimers Disease presents a detailed characterization of a new drug discovery tool for Alzheimer's disease. It demonstrates that an abnormal form of tau protein, as it occurs in Alzheimer's disease, can be produced in very simple cell models in an unambiguous way. Most importantly, it also shows an example of a chemical compound, found in nature, which is highly effective to completely suppress the abnormal changes of tau.

A simple cellular assay for the pathological modification of tau protein by abnormal hyperphosphorylation, as seen in Alzheimers disease and a variety of other neurological disorders (tauopathies), has been developed by researchers at Sirenade Pharmaceuticals AG in Munich, Germany. The assay can be used to screen for drugs against these disorders, and the discovery of a very effective small molecule is described as an example.

Tau proteins are a family of neuron-specific proteins believed to play an important role in the organization of the skeleton of nerve cells. This protein has been known to be abnormally modified in degenerating neurons in Alzheimers disease in a process called neurofibrillary degeneration. This form of neurodegeneration is thought to be a dominant cause of the massive loss of brain mass and function in many dementias, and its inhibition can be expected to change the prognosis of Alzheimers disease significantly.

Cell models are essential tools to analyze the molecular mechanisms involved in specific disease processes, and also the mechanisms of drugs, which act against them. For the process of tau hyperphosphorylation, credible models with utility for drug discovery have not been established to date. The model developed at Sirenade AG under the leadership of Dr. Hanno Roder, now at TauTaTis, Inc., fills this important gap.


'/>"/>

Contact: Astrid Engelen
a.engelen@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Page: 1

Related medicine news :

1. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
2. LCA Hails International Investigators Studying Lung Cancer
3. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
4. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
5. WRAIR investigators pioneering work on an exciting new class of antimalarial compounds
6. American Cancer Society awards research grants to 133 investigators at 84 institutions nationwide
7. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
8. Wellcorps International Unveils New Nutritional Supplements
9. Edwards Plan on AIDS Unveiled Today
10. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
11. Rice unveils $100 million initiative for world health technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... Excellence (CoE) with the latest Artificial Intelligence (AI) thinking, announced today the launch ... and easy access to essential information that offers a more comprehensive understanding of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Renal ... for people who have kidney disease. The theme “Describe a positive decision that ... Entrants needed to meet only one qualification— to have been diagnosed with ...
(Date:9/20/2017)... Houston, TX (PRWEB) , ... September 20, 2017 ... ... the date of the much-anticipated fall event , Look Awesome This Autumn ... demonstrations, personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of ... recently unveiled a redesigned website. The new site – still located at ... architects, contractors and other industry users that Garland serves. , After an ambitious ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short time since going on ... positive feedback from customers trying the product for the first time, and others who ... developed by neurosurgeon Shawn Moore, MD, for everyone from athletes at risk from multiple ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: